

## Special Issue

# Antibiotic Resistance and Therapy for *Helicobacter pylori* Infection

### Message from the Guest Editors

Potential topics for this Special Issue include but are not limited to:

- Alternative and complementary therapies for the treatment of *H. pylori* in the context of antibiotic resistance;
- New drug targets for *H. pylori* treatment in the post-antibiotic era;
- Molecular-based antibiotic susceptibility testing techniques for *H. pylori*;
- Mechanisms of *H. pylori* resistance: phenotypic/physiological changes in genomic mechanisms;
- Supplementation of *H. pylori* antibiotic therapy using probiotics;
- Clinical implication of drug resistance for *H. pylori* management.

The issue welcomes various types of submissions, such as original research papers, short communications, reviews, case reports, and perspectives.

Keywords:

- *H. pylori*
- antibiotic resistance
- alternative therapy
- drug targets
- probiotics

---

### Guest Editors

Prof. Dr. Stella I. Smith

Molecular Biology and Biotechnology Department, Yaba, Nigeria

Prof. Dr. Yoshio Yamaoka

Department of Environmental and Preventive Medicine, Oita University  
Faculty of Medicine, Idaigaoka, Hasama-machi, Yufu, Oita 879-5593,  
Japan

---

### Deadline for manuscript submissions

closed (30 June 2023)



## Antibiotics

---

an Open Access Journal  
by MDPI

---

Impact Factor 4.6  
CiteScore 8.7  
Indexed in PubMed



[mdpi.com/si/109968](https://mdpi.com/si/109968)

*Antibiotics*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[antibiotics@mdpi.com](mailto:antibiotics@mdpi.com)

[mdpi.com/journal/  
antibiotics](https://mdpi.com/journal/antibiotics)





# Antibiotics

---

an Open Access Journal  
by MDPI

---

Impact Factor 4.6  
CiteScore 8.7  
Indexed in PubMed



[mdpi.com/journal/  
antibiotics](https://mdpi.com/journal/antibiotics)



## About the Journal

### Message from the Editor-in-Chief

There are very few fields that attract as much attention as scientific endeavor related to antibiotic discovery, use and preservation. The public, patients, scientists, clinicians, policy-makers, NGOs, governments, and supra-governmental organizations are all focusing intensively on it: all are concerned that we use our existing agents more effectively, and develop and evaluate new interventions in time to face emerging challenges for the benefit of present and future generations. We need every discipline to contribute and collaborate: molecular, microbiological, clinical, epidemiological, geographic, economic, social scientific and policy disciplines are all key. *Antibiotics* is a nimble, inclusive and rigorous indexed journal as an enabling platform for all who can contribute to solving the greatest broad concerns of the modern world.

---

### Editor-in-Chief

Prof. Dr. Nicholas Dixon  
School of Chemistry and Molecular Bioscience, University of  
Wollongong, Wollongong, NSW 2522, Australia

---

### Author Benefits

#### Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q1 (Infectious Diseases) / CiteScore - Q1 (General Pharmacology, Toxicology and Pharmaceutics)